Preferences for substance

Print 26 November 2013
Maria Dranishnikova, Vedomodti

Preference of 15% can get the company that packaged medicines in Russia ( these preferences will be valid until the end of 2014 - after such producers cease to be considered local , say two members of yesterday's meeting at Manturov), 30 % - manufacturers of finished dosage forms , 40 % - establish a complete production cycle , ie, including the production of substances. 

In 2012, the Russian pharmaceutical market reached 773 billion rubles . , Of this amount, 236 billion rubles . had a segment of the public procurement , analysts estimate DSM Group. The share of imported drugs on the market - 76%. Approximately 450 foreign companies operating in Russia , production of finished forms localized about 50 companies , of which about 20 have their own production , 30 - contract , still only about 30 in the country packed medicines DSM Group says CEO Sergei Shuljak . 

Now for all acts of domestic producers a 15% preference if the winner of the auction becomes a local manufacturer, it enters into a contract at the price established in the course of trading and foreign must give a 15% discount . 

Order granting preferences produces Economic Development. Ministry of Economic Development Ministry of Industry sent in their proposals , said ministry spokesman . The representative of the Ministry of Economic Development has not responded to the request , "Vedomosti" . 

The proposed measures will contribute to the development of domestic pharmaceutical production and encourage foreign producers to pass on the full cycle of production of medicines in Russia , explains Manturov . This may affect companies that are directly involved in the auction , said deputy director of Stada CIS Ivan Glushkov . Drug prices may fall by about 30 %, while the share of domestic drugs on the market to grow , says co-owner of the developer and manufacturer of medicines " Biocad " Dmitry Morozov . 

Premium of 10% for the organization of a full production cycle is not entirely true , says CEO of pharmaceutical company "R -Pharm " Vasily Ignatiev. The world's largest manufacturer of substances - China , Russia industry will have to create from scratch , he explains. The cost of building a plant to produce substances Ignatiev valued at approximately $ 100 million 

Author: Maria Dranishnikova, www.vedomosti.ru

Source

Return